Investing for Commercial Success as an Emerging Company

When it comes to launching a pharmaceutical product in today’s market—especially as an emerging company—strategic investment can make all the difference.

Drawing from a recent study on investing for commercial success, Michael Sarshad, Managing Director in the Commercial Advisory Group at Syneos Health, discusses the key factors for successfully launching a drug in today's market; the importance of strategic investment, timing and team experience in exceeding launch forecasts; and the diverse areas where this investment is crucial, from medical affairs and market access to clinical strategy and supply chain logistics.

Tune in for expert insights into the intricacies of launching pharmaceutical products and how strategic investment can make all the difference.

For more of our insights on launch and commercialization, check out this content on our Insights Hub: 

Investing for Launch Success: The “Goldilocks” Ratio

Investing for Launch Success: Tailoring Your Strategy for Europe

Good Science Is Not Good Enough: For Emerging Companies, Differentiation Requires a Commercial Value Creation Story

Supporting the Launch of Biosimilars

WEBINAR | The Three Perils of Cross-Functional Commercialization: Time, Insight and Integration

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.